Insider Trading Alert - ALJ, REGN And PRSC Traded By Insiders - TheStreet

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Nov. 26, 2014, 114 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $187.00 to $173,041,515.00.

Highlighted Stocks Traded by Insiders:

Alon USA Energy (ALJ) - FREE Research Report

Alon Israel Oil Company, Ltd., who is 10% Owner at Alon USA Energy, sold 443,851 shares at $15.68 on Nov. 26, 2014. Following this transaction, the 10% Owner owned 37.5 million shares meaning that the stake was reduced by 1.17% with the 443,851-share transaction.

The shares most recently traded at $15.47, down $0.21, or 1.34% since the insider transaction. Historical insider transactions for Alon USA Energy go as follows:

  • 4-Week # shares sold: 468,851
  • 12-Week # shares bought: 4,000
  • 12-Week # shares sold: 468,851
  • 24-Week # shares bought: 4,000
  • 24-Week # shares sold: 811,551

The average volume for Alon USA Energy has been 1.2 million shares per day over the past 30 days. Alon USA Energy has a market cap of $1.1 billion and is part of the basic materials sector and energy industry. Shares are down 5.5% year-to-date as of the close of trading on Tuesday.

Alon USA Energy, Inc. operates as an independent refiner and marketer of petroleum products primarily in the South Central, Southwestern, and the Western regions of the United States. The company operates in three segments: Refining and Marketing, Asphalt, and Retail. The stock currently has a dividend yield of 2.56%. The company has a P/E ratio of 65.1. Currently, there is 1 analyst who rates Alon USA Energy a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ALJ - FREE

TheStreet Quant Ratings

rates Alon USA Energy as a

buy

. The company's strengths can be seen in multiple areas, such as its increase in net income, good cash flow from operations, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full

Alon USA Energy Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Regeneron Pharmaceuticals (REGN) - FREE Research Report

Poon Christine A, who is Director at Regeneron Pharmaceuticals, bought 400 shares at $410.00 on Nov. 26, 2014. Following this transaction, the Director owned 655 shares meaning that the stake was boosted by 156.86% with the 400-share transaction.

The shares most recently traded at $415.84, up $5.84, or 1.4% since the insider transaction. Historical insider transactions for Regeneron Pharmaceuticals go as follows:

  • 4-Week # shares bought: 400
  • 4-Week # shares sold: 54,577
  • 12-Week # shares bought: 400
  • 12-Week # shares sold: 54,577
  • 24-Week # shares bought: 400
  • 24-Week # shares sold: 80,251

The average volume for Regeneron Pharmaceuticals has been 848,500 shares per day over the past 30 days. Regeneron Pharmaceuticals has a market cap of $40.8 billion and is part of the health care sector and drugs industry. Shares are up 50.05% year-to-date as of the close of trading on Tuesday.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. The company has a P/E ratio of 138.4. Currently, there are 10 analysts who rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on REGN - FREE

TheStreet Quant Ratings

rates Regeneron Pharmaceuticals as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Regeneron Pharmaceuticals Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Providence Service (PRSC) - FREE Research Report

Wilson Robert E, who is Chief Financial Officer at Providence Service, bought 7,500 shares at $36.86 on Nov. 26, 2014. Following this transaction, the Chief Financial Officer owned 7,500 shares meaning that the stake was boosted by 100% with the 7,500-share transaction.

The shares most recently traded at $37.08, up $0.22, or 0.59% since the insider transaction. Historical insider transactions for Providence Service go as follows:

  • 4-Week # shares bought: 7,500
  • 4-Week # shares sold: 5,750
  • 12-Week # shares bought: 7,500
  • 12-Week # shares sold: 5,750
  • 24-Week # shares bought: 7,500
  • 24-Week # shares sold: 5,750

The average volume for Providence Service has been 178,900 shares per day over the past 30 days. Providence Service has a market cap of $579.8 million and is part of the health care sector and health services industry. Shares are up 39.81% year-to-date as of the close of trading on Tuesday.

The Providence Service Corporation provides and manages government sponsored human services and non-emergency transportation services. The company operates in two segments, Human Services and Non-Emergency Transportation Services (NET Services). The company has a P/E ratio of 32.1. Currently, there are 3 analysts who rate Providence Service a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PRSC - FREE

TheStreet Quant Ratings

rates Providence Service as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and generally higher debt management risk. Get the full

Providence Service Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null